Search

Your search keyword '"Döhner, Konstanze"' showing total 1,709 results

Search Constraints

Start Over You searched for: Author "Döhner, Konstanze" Remove constraint Author: "Döhner, Konstanze"
1,709 results on '"Döhner, Konstanze"'

Search Results

202. Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

204. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1Mutated AML - Results of the European Harmony Alliance

206. Quantitative analyses of DAPK1 methylation in AML and MDS

208. Higher Dose of CPX-351 Is Associated with Prolonged Hematologic Recovery: Results from an Interim Safety Analysis of the Randomized, Phase III AMLSG 30-18 Trial

209. Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)²

210. Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

211. Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication (FLT3-ITD+ AML) Treated with Additional Midostaurin

212. Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

214. Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

215. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

217. TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition

219. Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study

220. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

221. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

225. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

228. UBTF::ATXN7L3gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

233. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML

235. Human Chromosome 7: DNA Sequence and Biology

238. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique.

240. Leitlinie - ICD10: D45 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

241. Leitlinie - ICD-10 D47.1 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

242. Primäre Myelofibrose (PFM)

244. The ParaHox gene Cdx4 induces acute erythroid leukemia in mice

245. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells

247. Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)

248. Post Transplantation Measurable Residual Disease (MRD) Monitoring Using Next-Generation Sequencing Is Highly Predictive for Relapseafter Allogeneic Stem Cell Transplantation

249. Loss of Phospholipase C Gamma 1 (PLCG1) Impairs AML1-ETO Induced Leukemia Stem Cell Self-Renewal

250. Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia

Catalog

Books, media, physical & digital resources